Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2011

Open Access 01-12-2011 | Research

Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis

Authors: Noemí Virgili, Juan F Espinosa-Parrilla, Pilar Mancera, Andrea Pastén-Zamorano, Javier Gimeno-Bayon, Manuel J Rodríguez, Nicole Mahy, Marco Pugliese

Published in: Journal of Neuroinflammation | Issue 1/2011

Login to get access

Abstract

Background

Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of the central nervous system (CNS) and is the leading cause of nontraumatic disability among young adults. Activated microglial cells are important effectors of demyelination and neurodegeneration, by secreting cytokines and others neurotoxic agents. Previous studies have demonstrated that microglia expresses ATP-sensitive potassium (KATP) channels and its pharmacological activation can provide neuroprotective and anti-inflammatory effects. In this study, we have examined the effect of oral administration of KATP channel opener diazoxide on induced experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.

Methods

Anti-inflammatory effects of diazoxide were studied on lipopolysaccharide (LPS) and interferon gamma (IFNγ)-activated microglial cells. EAE was induced in C57BL/6J mice by immunization with myelin oligodendrocyte glycoprotein peptide (MOG35-55). Mice were orally treated daily with diazoxide or vehicle for 15 days from the day of EAE symptom onset. Treatment starting at the same time as immunization was also assayed. Clinical signs of EAE were monitored and histological studies were performed to analyze tissue damage, demyelination, glial reactivity, axonal loss, neuronal preservation and lymphocyte infiltration.

Results

Diazoxide inhibited in vitro nitric oxide (NO), tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) production and inducible nitric oxide synthase (iNOS) expression by activated microglia without affecting cyclooxygenase-2 (COX-2) expression and phagocytosis. Oral treatment of mice with diazoxide ameliorated EAE clinical signs but did not prevent disease. Histological analysis demonstrated that diazoxide elicited a significant reduction in myelin and axonal loss accompanied by a decrease in glial activation and neuronal damage. Diazoxide did not affect the number of infiltrating lymphocytes positive for CD3 and CD20 in the spinal cord.

Conclusion

Taken together, these results demonstrate novel actions of diazoxide as an anti-inflammatory agent, which might contribute to its beneficial effects on EAE through neuroprotection. Treatment with this widely used and well-tolerated drug may be a useful therapeutic intervention in ameliorating MS disease.
Appendix
Available only for authorised users
Literature
1.
Lassmann H: Multiple sclerosis: is there neurodegeneration independent from inflammation?. J Neurol Sci. 2007, 259: 3-6. 10.1016/j.jns.2006.08.016.CrossRefPubMed
2.
Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007, 8: 57-69. 10.1038/nrn2038.CrossRefPubMed
3.
Ransohoff RM, Perry VH: Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009, 27: 119-145. 10.1146/annurev.immunol.021908.132528.CrossRefPubMed
4.
Wulff H, Zhorov BS: K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev. 2008, 108: 1744-1773. 10.1021/cr078234p.PubMedCentralCrossRefPubMed
5.
Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, Cahalan MD, Chandy KG: Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem. 2000, 275: 37137-37149. 10.1074/jbc.M003941200.CrossRefPubMed
6.
Wulff H, Pennington M: Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel. 2007, 10: 438-445.PubMed
7.
Bittner S, Bobak N, Herrmann AM, Gobel K, Meuth P, Hohn KG, Stenner MP, Budde T, Wiendl H, Meuth SG: Upregulation of K2P5.1 potassium channels in multiple sclerosis. Ann Neurol. 2010, 68: 58-69. 10.1002/ana.22010.CrossRefPubMed
8.
Clement JP, Kunjilwar K, Gonzalez G, Schwanstecher M, Panten U, Aguilar-Bryan L, Bryan J: Association and stoichiometry of K(ATP) channel subunits. Neuron. 1997, 18: 827-838. 10.1016/S0896-6273(00)80321-9.CrossRefPubMed
9.
Brayden JE: Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol. 2002, 29: 312-316. 10.1046/j.1440-1681.2002.03650.x.CrossRefPubMed
10.
Ashcroft FM: K(ATP) channels and insulin secretion: a key role in health and disease. Biochem Soc Trans. 2006, 34: 243-246.CrossRefPubMed
11.
Nichols CG: KATP channels as molecular sensors of cellular metabolism. Nature. 2006, 440: 470-476. 10.1038/nature04711.CrossRefPubMed
12.
Busija DW, Gaspar T, Domoki F, Katakam PV, Bari F: Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning. Adv Drug Deliv Rev. 2008, 60: 1471-1477. 10.1016/j.addr.2008.03.020.PubMedCentralCrossRefPubMed
13.
Xie J, Duan L, Qian X, Huang X, Ding J, Hu G: K(ATP) channel openers protect mesencephalic neurons against MPP+-induced cytotoxicity via inhibition of ROS production. J Neurosci Res. 2010, 88: 428-437. 10.1002/jnr.22213.CrossRefPubMed
14.
Zawar C, Plant TD, Schirra C, Konnerth A, Neumcke B: Cell-type specific expression of ATP-sensitive potassium channels in the rat hippocampus. J Physiol. 1999, 514 (Pt 2): 327-341.PubMedCentralPubMed
15.
Levin BE, Dunn-Meynell AA, Routh VH: Brain glucosensing and the KATP channel. Nat Neurosci. 2001, 4: 459-460.PubMed
16.
Liss B, Haeckel O, Wildmann J, Miki T, Seino S, Roeper J: K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat Neurosci. 2005, 8: 1742-1751. 10.1038/nn1570.CrossRefPubMed
17.
Ramonet D, Rodríguez MJ, Pugliese M, Mahy N: Putative glucosensing property in rat and human activated microglia. Neurobiol Dis. 2004, 17: 1-9. 10.1016/j.nbd.2003.11.019.CrossRefPubMed
18.
Goodman Y, Mattson MP: K+ channel openers protect hippocampal neurons against oxidative injury and amyloid beta-peptide toxicity. Brain Res. 1996, 706: 328-332. 10.1016/0006-8993(95)01367-9.CrossRefPubMed
19.
Roseborough G, Gao D, Chen L, Trush MA, Zhou S, Williams GM, Wei C: The mitochondrial K-ATP channel opener, diazoxide, prevents ischemia-reperfusion injury in the rabbit spinal cord. Am J Pathol. 2006, 168: 1443-1451. 10.2353/ajpath.2006.050569.PubMedCentralCrossRefPubMed
20.
Zhou F, Yao HH, Wu JY, Ding JH, Sun T, Hu G: Opening of microglial K(ATP) channels inhibits rotenone-induced neuroinflammation. J Cell Mol Med. 2008, 12: 1559-1570. 10.1111/j.1582-4934.2007.00144.x.PubMedCentralCrossRefPubMed
21.
Robin E, Simerabet M, Hassoun SM, Adamczyk S, Tavernier B, Vallet B, Bordet R, Lebuffe G: Postconditioning in focal cerebral ischemia: Role of the mitochondrial ATP-dependent potassium channel. Brain Res. 2011, 1375: 137-146.CrossRefPubMed
22.
Ashcroft FM, Gribble FM: New windows on the mechanism of action of K(ATP) channel openers. Trends Pharmacol Sci. 2000, 21: 439-445. 10.1016/S0165-6147(00)01563-7.CrossRefPubMed
23.
Bergsten P, Gylfe E, Wesslen N, Hellman B: Diazoxide unmasks glucose inhibition of insulin release by counteracting entry of Ca2+. Am J Physiol. 1988, 255: E422-E427.PubMed
24.
Petit P, Loubatieres-Mariani MM: Potassium channels of the insulin-secreting B cell. Fundam Clin Pharmacol. 1992, 6: 123-134. 10.1111/j.1472-8206.1992.tb00103.x.CrossRefPubMed
25.
Warter A, Gillet B, Weryha A, Hagbe P, Simler M: Hypoglycemia due to insulinoma complicated with hepatic metastases. Excellent results after 20 months of treatment with diazoxide. Ann Med Interne (Paris). 1970, 121: 927-934.
26.
27.
Hanley PJ, Mickel M, Löffler M, Brandt U, Daut J: K(ATP) channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart. J Physiol. 2002, 542: 735-41. 10.1113/jphysiol.2002.023960.PubMedCentralCrossRefPubMed
28.
Minners J, Lacerda L, Yellon DM, Opie LH, McLeod CJ, Sack MN: Diazoxide-induced respiratory inhibition - a putative mitochondrial K(ATP) channel independent mechanism of pharmacological preconditioning. Mol Cell Biochem. 2007, 294: 11-8. 10.1007/s11010-005-9066-6.CrossRefPubMed
29.
Saura J, Tusell JM, Serratosa J: High-yield isolation of murine microglia by mild trypsinization. Glia. 2003, 44: 183-189. 10.1002/glia.10274.CrossRefPubMed
30.
Holmuhamedov EL, Jahangir A, Oberlin A, Komarov A, Colombini M, Terzic A: Potassium channel openers are uncoupling protonophores: implication in cardioprotection. FEBS Lett. 2004, 568: 167-170. 10.1016/j.febslet.2004.05.031.CrossRefPubMed
31.
32.
Thomzig A, Laube G, Pruss H, Veh RW: Pore-forming subunits of K-ATP channels, Kir6.1 and Kir6.2, display prominent differences in regional and cellular distribution in the rat brain. J Comp Neurol. 2005, 484: 313-330. 10.1002/cne.20469.CrossRefPubMed
33.
Fogal B, McClaskey C, Yan S, Yan H, Rivkees SA: Diazoxide promotes oligodendrocyte precursor cell proliferation and myelination. PLoS One. 2010, 5: e10906-10.1371/journal.pone.0010906.PubMedCentralCrossRefPubMed
34.
Liu X, Wu JY, Zhou F, Sun XL, Yao HH, Yang Y, Ding JH, Hu G: The regulation of rotenone-induced inflammatory factor production by ATP-sensitive potassium channel expressed in BV-2 cells. Neurosci Lett. 2006, 394: 131-135. 10.1016/j.neulet.2005.10.018.CrossRefPubMed
35.
Bal-Price A, Brown GC: Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci. 2001, 21: 6480-91.PubMed
36.
Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R: Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010, 7: 30-10.1186/1742-2094-7-30.PubMedCentralCrossRefPubMed
37.
Hill KE, Zollinger LV, Watt HE, Carlson NG, Rose JW: Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J Neuroimmunol. 2004, 151: 171-179. 10.1016/j.jneuroim.2004.02.005.CrossRefPubMed
38.
Tran EH, Hardin-Pouzet H, Verge G, Owens T: Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J Neuroimmunol. 1997, 74: 121-129. 10.1016/S0165-5728(96)00215-9.CrossRefPubMed
39.
Fisher J, Mizrahi T, Schori H, Yoles E, Levkovitch-Verbin H, Haggiag S, Revel M, Schwartz M: Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility. J Neuroimmunol. 2001, 119: 1-9. 10.1016/S0165-5728(01)00342-3.CrossRefPubMed
40.
Quintana A, Muller M, Frausto RF, Ramos R, Getts DR, Sanz E, Hofer MJ, Krauthausen M, King NJ, Hidalgo J, Campbell IL: Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2009, 183: 2079-2088. 10.4049/jimmunol.0900242.CrossRefPubMed
41.
Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T: Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol. 1997, 27: 905-913. 10.1002/eji.1830270416.CrossRefPubMed
42.
Korner H, Lemckert FA, Chaudhri G, Etteldorf S, Sedgwick JD: Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol. 1997, 27: 1973-1981. 10.1002/eji.1830270822.CrossRefPubMed
43.
Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, Szymkowski DE, Bethea JR: Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain. 2011, 134: 2736-2754. 10.1093/brain/awr199.PubMedCentralCrossRefPubMed
44.
45.
Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006, 38: 1654-1661. 10.1016/j.biocel.2006.03.021.CrossRefPubMed
46.
Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H: TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 2007, 4: e124-10.1371/journal.pmed.0040124.PubMedCentralCrossRefPubMed
47.
Bogie JF, Stinissen P, Hellings N, Hendriks JJ: Myelin-phagocytosing macrophages modulate autoreactive T cell proliferation. J Neuroinflammation. 2011, 8: 85-10.1186/1742-2094-8-85.PubMedCentralCrossRefPubMed
48.
Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, Martino G, Schwartz M: Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci. 2006, 31: 149-160. 10.1016/j.mcn.2005.10.006.CrossRefPubMed
49.
Doring A, Yong VW: The good, the bad and the ugly. Macrophages/microglia with a focus on myelin repair. Front Biosci (Schol Ed). 2011, 3: 846-856.CrossRef
50.
Tokuhara N, Namiki K, Uesugi M, Miyamoto C, Ohgoh M, Ido K, Yoshinaga T, Yamauchi T, Kuromitsu J, Kimura S, Miyamoto N, Kasuya Y: N-type calcium channel in the pathogenesis of experimental autoimmune encephalomyelitis. J Biol Chem. 2010, 285: 33294-33306. 10.1074/jbc.M109.089805.PubMedCentralCrossRefPubMed
51.
Gadjanski I, Boretius S, Williams SK, Lingor P, Knoferle J, Sattler MB, Fairless R, Hochmeister S, Suhs KW, Michaelis T, Frahm J, Storch MK, Bahr M, Diem R: Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis. Ann Neurol. 2009, 66: 81-93. 10.1002/ana.21668.CrossRefPubMed
52.
Sun XL, Zeng XN, Zhou F, Dai CP, Ding JH, Hu G: KATP channel openers facilitate glutamate uptake by GluTs in rat primary cultured astrocytes. Neuropsychopharmacology. 2008, 33: 1336-1342. 10.1038/sj.npp.1301501.CrossRefPubMed
53.
Zhang S, Liang R, Zhou F, Huang X, Ding JH, Hu G: Reversal of rotenone-induced dysfunction of astrocytic connexin43 by opening mitochondrial ATP-sensitive potassium channels. Cell Mol Neurobiol. 2011, 31: 111-117. 10.1007/s10571-010-9560-6.CrossRefPubMed
54.
Ben Ari Y, Krnjevic K, Crepel V: Activators of ATP-sensitive K+ channels reduce anoxic depolarization in CA3 hippocampal neurons. Neuroscience. 1990, 37: 55-60. 10.1016/0306-4522(90)90191-6.CrossRefPubMed
55.
Nagy K, Kis B, Rajapakse NC, Bari F, Busija DW: Diazoxide preconditioning protects against neuronal cell death by attenuation of oxidative stress upon glutamate stimulation. J Neurosci Res. 2004, 76: 697-704. 10.1002/jnr.20120.CrossRefPubMed
56.
Raval AP, Dave KR, DeFazio RA, Perez-Pinzon MA: EpsilonPKC phosphorylates the mitochondrial K(+) (ATP) channel during induction of ischemic preconditioning in the rat hippocampus. Brain Res. 2007, 1184: 345-353.PubMedCentralCrossRefPubMed
57.
Wang L, Zhu QL, Wang GZ, Deng TZ, Chen R, Liu MH, Wang SW: The protective roles of mitochondrial ATP-sensitive potassium channels during hypoxia-ischemia-reperfusion in brain. Neurosci Lett. 2011, 491: 63-67. 10.1016/j.neulet.2010.12.065.CrossRefPubMed
58.
Liu D, Pitta M, Lee JH, Ray B, Lahiri DK, Furukawa K, Mughal M, Jiang H, Villarreal J, Cutler RG, Greig NH, Mattson MP: The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis. 2010, 22: 443-457.PubMedCentralPubMed
59.
Bertolino M, Baraldi M, Parenti C, Braghiroli D, DiBella M, Vicini S, Costa E: Modulation of AMPA/kainate receptors by analogues of diazoxide and cyclothiazide in thin slices of rat hippocampus. Receptor Channels. 1993, 1: 267-78.
60.
Ammala C, Moorhouse A, Gribble F, Ashfield R, Proks P, Smith PA, Sakura H, Coles B, Ashcroft SJ, Ashcroft FM: Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels. Nature. 1996, 379: 545-548. 10.1038/379545a0.CrossRefPubMed
61.
Chen M, Dong Y, Simard JM: Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci. 2003, 23: 8568-8577.PubMed
62.
Gold R, Linington C, Lassmann H: Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006, 129: 1953-71. 10.1093/brain/awl075.CrossRefPubMed
63.
Juedes AE, Ruddle NH: Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J Immunol. 2001, 166: 5168-5175.CrossRefPubMed
64.
Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD: Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med. 1997, 186: 1585-1590. 10.1084/jem.186.9.1585.PubMedCentralCrossRefPubMed
Metadata
Title
Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis
Authors
Noemí Virgili
Juan F Espinosa-Parrilla
Pilar Mancera
Andrea Pastén-Zamorano
Javier Gimeno-Bayon
Manuel J Rodríguez
Nicole Mahy
Marco Pugliese
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2011
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-8-149

Other articles of this Issue 1/2011

Journal of Neuroinflammation 1/2011 Go to the issue

Research

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders

Research

Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis

Research

Increased local concentration of complement C5a contributes to incisional pain in mice

Research

Inhibitory effect of a tyrosine-fructose Maillard reaction product, 2,4-bis(p-hydroxyphenyl)-2-butenal on amyloid-β generation and inflammatory reactions via inhibition of NF-κB and STAT3 activation in cultured astrocytes and microglial BV-2 cells

Research

Tissue inhibitor of metalloproteinases-3 mediates the death of immature oligodendrocytes via TNF-α/TACE in focal cerebral ischemia in mice

Research

A dual role for microglia in promoting tissue inhibitor of metalloproteinase (TIMP) expression in glial cells in response to neuroinflammatory stimuli